share_log

HC Wainwright & Co. Reiterates Buy on Keros Therapeutics, Maintains $100 Price Target

Benzinga ·  21:07  · Ratings

HC Wainwright & Co. analyst Andrew Fein reiterates Keros Therapeutics (NASDAQ:KROS) with a Buy and maintains $100 price target.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment